StageZero Life Sciences Ltd(SZLSF)
USD --+0.00%
Reward38Moderate
Risk66Medium-High
📊75%Data
Revenue down 33% YoY
SZLSF
+0.0 · +0.00%
USD · PINK
StageZero Life Sciences Ltd | Healthcare
Value Trap
Market Cap:61766
ℹ️
Reward Rating
38
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
66
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SZLSF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is StageZero Life Sciences Ltd?

, a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe.

SZLSF · Verdict

Limited reward · elevated risk

SZLSF stands out on volatility and valuation, but watch the cash flow signal.

Based on 88% data coverage

SZLSF · Verdict

What’s working & what to watch

Strengths 2

  • Volatility95/100

    Top decile vs peers

  • Valuation89/100

    P/E 3.5×

Watchouts 4

  • Cash flow6/100

    -28% free-cash-flow margin

  • Profitability9/100

    -435% net margin · -169% ROE

  • Balance sheet19/100

    Current ratio 0.04

  • Growth25/100

    Rev -11.5% CAGR · earnings +22.2%

Model-based scoring. For information only — not financial advice.

What is StageZero Life Sciences Ltd?

, a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 61.77K.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (38)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap61.77K
P/E RatioN/A
Dividend YieldN/A
52 Week High0.05
52 Week Low0.0005
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding124M
No. of Employees40
IndustryDiagnostics & Research
ExchangePINK
Beta0.345
CurrencyUSD